Clinical Trial Update: A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM) [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluated the efficacy and safety of the RVD regimen with or without panobinostat in transplant-eligible, newly diagnosed multiple myeloma; t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Farydak (panobinostat)
• Revlimid (lenalidomide)
• Velcade (bortezomib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Multiple Myeloma | Phase 2 | Status: TERMINATED | Results posted: 2018-07-24